Hormone Therapy Labeling Should Include "Black Box" Warning On Dementia Risk, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA requests labeling warning on increased dementia risk with use of estrogen and combination estrogen/progestin products. The updated labeling template incorporates findings from Women’s Health Initiative Memory Study.